28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业

Core Viewpoint - The joint venture plan between Kangtai Biological (300601.SZ) and AstraZeneca has been terminated due to significant market changes and high investment risks in the vaccine industry [3][4]. Group 1: Joint Venture Details - Kangtai Biological and AstraZeneca planned to establish a joint venture in Beijing with a registered capital of approximately 345 million RMB (about 50 million USD) and a total investment of around 400 million USD (approximately 2.76 billion RMB) [3]. - The joint venture was intended to develop, register, and commercialize innovative vaccines, including AstraZeneca's RSV and hMPV combination vaccine in China [3]. Group 2: Reasons for Termination - The termination was attributed to severe market environment changes and significant downward pressure on the industry, making new investments in the vaccine sector highly risky [4]. - Currently, there are no approved vaccines for RSV and hMPV in the Chinese market, and many domestic vaccine companies focus on traditional products, leading to increased market homogenization [4]. Group 3: Financial Outlook - Kangtai Biological expects a net profit attributable to shareholders of 49 million to 73 million RMB for 2025, representing a year-on-year decline of 63.80% to 75.70% [4]. - Recent data from the China Chamber of Commerce for Import and Export of Medicines and Health Products indicates a decline in the batch issuance and import volume of vaccines in 2025, primarily due to multinational companies reducing or pausing imports to consume existing inventory [4]. Group 4: AstraZeneca's Investment Plans - Despite the termination of the joint venture, AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to expand its pharmaceutical production and R&D footprint [5].